PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1139
https://www.valueinhealthjournal.com/article/S1098-3015(19)33517-X/fulltext
Title :
PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33517-X&doi=10.1016/j.jval.2019.09.1139
First page :
Section Title :
Open access? :
No
Section Order :
11000